Last Price$20.72.1%
Market Cap$972.8M
$440.0K
N/A
($85.2M)
+364.8% YoY
($291.7M)
Net Debt to FCF - 4.3x
($68.5M)
(15,574.8% margin)
ELVN Income Statement
ELVN Income Statement Overview
Annual
Quarterly
LTM
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
ELVN Income statement key metrics
Annual
Quarterly
LTM
ELVN Balance Sheet
ELVN Balance Sheet Overview
Annual
Quarterly
LTM
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Assets
Liabilities
Total assets
$271.9M
Current assets ($266.2M, 97.9% of total)
$253.1M (93.1%)
$0.0 (0.0%)
Other current assets
$13.0M (4.8%)
Non-current assets ($5,716.0K, 2.1% of total)
$0.0 (0.0%)
$1,062.0K (0.4%)
$0.0 (0.0%)
Other non-current assets
$4,654.0K (1.7%)
Financial position
($252.8M)
Cash & Short-term
Investments
Total Debt
ELVN Balance Sheet Metrics
Annual
Quarterly
LTM
ELVN Cash Flow Statement
ELVN Cash Flow Statement Overview
Annual
Quarterly
LTM
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
$24.6M Net Change in Cash
ELVN Cash Flow Statement key metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
($61.3M) +137.4% YoY
Capital Expenditure (CAPEX)
($149.0K) -75.7% YoY
Free Cash Flow (FCF)
($61.4M) +132.4% YoY
ELVN Financials
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.6 | 0.3 |
% margin | 0.0 0.0% | 0.0 0.0% | (0.0) 0.0% | (0.1) 0.0% | (0.1) 0.0% | (0.6) 0.0% | (0.3) 0.0% |
| Operating Expenses | 8.9 | 10.7 | 24.1 | 9.3 | 24.8 | 38.8 | 83.5 |
| Research & Development Expenses (R&D) | 7.9 | 8.2 | 19.0 | 8.2 | 20.5 | 31.0 | 64.6 |
| Selling, General & Administrative Expenses (SG&A) | 1.0 | 2.4 | 5.1 | 1.1 | 4.3 | 7.8 | 19.0 |
% margin | (8.9) 0.0% | (10.7) 0.0% | (24.1) 0.0% | (9.3) 0.0% | (24.8) 0.0% | (38.8) 0.0% | (83.5) 0.0% |
| Interest Income | 0.0 | 0.0 | 0.6 | 0.0 | 0.0 | 1.1 | 12.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax Income | 0.2 | (11.3) | (23.5) | (19.0) | (24.7) | (37.7) | (71.6) |
% effective tax rate | 0.2 100.0% | (0.8) 7.2% | 0.7 (2.8%) | (0.0) 0.2% | (0.0) 0.1% | 0.1 (0.2%) | 0.0 0.0% |
% margin | 0.0 0.0% | (11.3) 0.0% | (23.5) 0.0% | (18.9) 0.0% | (24.7) 0.0% | (37.8) 0.0% | (71.6) 0.0% |
| EPS | 0.00 | (2.62) | (5.43) | (14.14) | (3.17) | (6.03) | (2.01) |
| Diluted EPS | 0.00 | (2.62) | (5.43) | (14.14) | (3.17) | (6.03) | (2.01) |
% margin | 0.2 0.0% | (11.3) 0.0% | (23.4) 0.0% | (9.3) 0.0% | (24.6) 0.0% | (38.6) 0.0% | (81.9) 0.0% |
FAQ
What is the Enliven Therapeutics, Inc. (ELVN) revenue?
The Enliven Therapeutics, Inc. (ELVN) revenue is $0.0, reflecting a year-over-year (YoY) growth of N/A.
What is the Enliven Therapeutics, Inc. (ELVN) Net Income?
The Enliven Therapeutics, Inc. (ELVN) Net Income is ($71.6M), showcasing a YoY growth of +89.6% YoY.
What is Enliven Therapeutics, Inc. (ELVN) net debt?
What is the Enliven Therapeutics, Inc. (ELVN) Free Cash Flow (FCF)?
The Enliven Therapeutics, Inc. (ELVN) Free Cash Flow (FCF) stands at ($61.4M), accounting for a N/A margin.